Effective in vivo anti-tumor activity of combined GSK126 and cisplatin treatment also enhanced overall survival of mice bearing BRCA1-deficient mouse mammary tumors, suggesting that EZH2 inhibition enhances the sensitivity to platinum drugs in EZH2-overexpressing breast tumors [14]. This evidence concerns the gene EZH2 and breast neoplasm.